Delivering Teclistamab in the Outpatient Setting
Freshta Poupal, RN, and Frannie Bell, NP, share their experiences with teclistamab in clinical practice.
Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma
Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.
Elizabeth Aronson Breaks Down Data From Behind Talquetamab Approval in Multiple Myeloma
Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MonumenTAL-1 study assessing talquetamab in multiple myeloma.
Selinexor Maintenance Demonstrates Efficacy in TP53 Wild-Type Advanced Endometrial Cancer Following Frontline Chemotherapy
Patients with TP53 wild-type endometrial cancer experienced a median progression-free survival of 27.4 months vs 5.2 months with placebo.
Early Intervention for CRS Is Key for Patients With Multiple Myeloma Receiving Bispecific Antibodies
Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.
Nurses Exchange Best Strategies in Improving Delivery of Hepatic Artery Infusion Pump Education
Kathleen Gander DNP, APRN, CNS; and Sarah Middlekauff, MSN, RN, OCN, relay their experiences in implementing a hepatic artery infusion pump educational intervention for oncology nurses.
Donna Catamero Discusses Managing Teclistamab-Induced CRS for Patients With Multiple Myeloma
Donna Catamero, ANP-BC, OCN, CCRC, outlines best management strategies for treating patients receiving teclistamab who experience cytokine release syndrome.
Monitoring CRS With Teclistamab Is a Priority in Caring for Patients With Multiple Myeloma
Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.
Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer
Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer
Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.
Adjuvant Nivolumab Continues to Minimize Recurrence for Patients With Muscle-Invasive Urothelial Cancer
Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.
Adding Pembrolizumab to Lenvatinib Yields Similar HRQOL Scores As Lenvatinib Alone in HCC
Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
Conversations Around Selinexor: Best Nursing Practices in Multiple Myeloma
In this episode of “The Vitals,” Daniel J. Verina, DNP, RN, MSN, ACNP-BC, discusses clinical pearls in caring for patients receiving selinexor, an XPO-1 inhibitor.
Satellite Clinical Trial Sites May Improve Minority Patient Accrual But Challenges Still Exist
Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.
Verina Underscores Best Nursing Practices With Targeted Therapies in Multiple Myeloma
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.
Oral and Dermatologic Toxicities Associated With Talquetamab Can Be Mitigated With Nurse Intervention
Through patient education tactics, oncology nurses can help patients with multiple myeloma mitigate the oral and dermatologic toxicities associated with talquetamab.
Nursing Considerations for Using Selinexor in Multiple Myeloma
An expert from the Tisch Cancer Institute highlights the importance of medication adherence, nausea management, and proper hydration for patients being treated with selinexor for relapsed or refractory multiple myeloma.
Cilta-Cel Induces Deep and Durable Responses in Patients with Multiple Myeloma
At 12 months, 97% patients treated with single infusions of cilta-cel had responded to the therapy.
Rusfertide Helps Combat Iron Deficiency and Improve Symptoms in Patients with Polycythemia Vera
Symptomatic iron deficiency, a key challenge in facing polycythemia vera, might be effectively treated with rusfertide.
Early Study Lays Groundwork for Boosting Immunotherapy Response
Regulating the fas protein may be the key in overcoming resistance in patients receiving immunotherapy treatment, such as CAR T-cell therapy.
JAK Inhibitors Build Momentum in Myelofibrosis Treatment
With additional JAK inhibitors under exploration in the myelofibrosis pipeline, such as momelotinib and pacritinib, FDA-approved options continue to be utilized heavily in the paradigm, explained John O. Mascarenhas, MD.
Ruxolitinib Discontinuation Worsens Myelofibrosis Outcomes, Highlighting Unmet Need
A United States population-based outcome analysis of real-world patients with myelofibrosis who had discontinued ruxolitinib (Jakafi) demonstrated an increase in morbidity burden and identified the risk factors of survival outcomes, according to John O. Mascarenhas, MD.
For Treatment of Bone Metastases, Include Palliative Care With Radiotherapy
For patients with painful bone metastases, an intervention combining palliative care with radiation oncology led to better results, according to preliminary findings from a new study.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512